<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04254913</url>
  </required_header>
  <id_info>
    <org_study_id>MT-1186-J05</org_study_id>
    <nct_id>NCT04254913</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy</brief_title>
  <official_title>Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Amyotrophic
      Lateral Sclerosis Patients with gastrostomy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentrations of edaravone</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time curve (AUC) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant (Kel) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRT) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance (CL/F) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent distribution volume at elimination phase (Vz/F) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent distribution volume at steady state (Vss/F) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative amount of drug excreted in urine (Ae) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative percentage of drug excreted in urine (Ae%) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent renal clearance (CLr/F) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse events and adverse drug reactions</measure>
    <time_frame>The provision of informed consent to Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Japanese Patients With ALS</condition>
  <arm_group>
    <arm_group_label>MT-1186</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive the edaravone oral suspension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-1186</intervention_name>
    <description>Suspension</description>
    <arm_group_label>MT-1186</arm_group_label>
    <other_name>Edaravone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The key criteria are listed below.

          -  Patients aged between 20 and 80 years at the time of informed consent

          -  Japanese patients

          -  Among patients with ALS, those &quot;Clinically definite ALS,&quot; &quot;Clinically probable ALS&quot; or
             &quot;Clinically probable-laboratory-supported ALS&quot; according to El Escorial Revised Airlie
             House criteria

          -  ALS Patients with gastrostomy

          -  Patients who can consent to contraception

          -  Patients who have thoroughly understood the contents of the study and voluntarily
             provided written informed consent to participate in the study

        Exclusion Criteria:

        The key criteria are listed below.

          -  Patients in whom the possibility could not be ruled out that the current symptoms were
             symptoms of a disease requiring differential diagnosis, such as cervical spondylosis
             and multifocal motor neuropathy

          -  Patients undergoing treatment for malignancy.

          -  Patients who have presence of clinically significant liver, heart, or renal disease
             requiring hospitalization (except ALS) and infections requiring antibiotics. Patients
             who have a problem in general condition and are judged ineligible by the Investigator

          -  Body mass index (BMI) of &lt;15.0 or &gt;30.0, or a body weight of &lt;40 kg

          -  Patients judged by the investigator (or subinvestigator) to be unsuitable for the
             study for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk, to prevent miscommunication,</last_name>
    <phone>please email:</phone>
    <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 2, 2020</last_update_submitted>
  <last_update_submitted_qc>February 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

